Growth Hormone for Osteoporosis Pseudoglioma Syndrome
Information source: University of Maryland
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Osteoporosis Pseudoglioma Syndrome
Intervention: Human recombinant growth hormone (Biological)
Phase: N/A
Status: Not yet recruiting
Sponsored by: University of Maryland Official(s) and/or principal investigator(s):
Elizabeth A Streeten, MD, Principal Investigator, Affiliation: University of Maryland School of Medicine, Division of Endocrinology
Overall contact:
Elizabeth A Streeten, MD, Phone: 410-328-6219, Email: estreete@medicine.umaryland.edu
Summary
Osteoporosis pseudoglioma (OPPG) syndrome is a rare autosomal recessive condition of
childhood osteoporosis and congenital blindness for which new treatments are needed. We have
found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that
growth hormone therapy will improve muscle mass and bone strength in OPPG.
Clinical Details
Official title: Trial of Growth Hormone for Osteoporosis Pseudoglioma Syndrome
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Bone quality by pQCT
Secondary outcome: Body fat percent
Eligibility
Minimum age: 4 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Osteoporosis pseudoglioma syndrome
- Age 4 years and above
- not on medication for osteoporosis
Exclusion Criteria:
- pregnant
- Age under 4 yrs
- Active malignancy
Locations and Contacts
Elizabeth A Streeten, MD, Phone: 410-328-6219, Email: estreete@medicine.umaryland.edu
University of Maryland School of Medicine, Baltimore, Maryland 21201, United States; Not yet recruiting
Elizabeth A Streeten, MD, Phone: 410-328-6219, Email: estreete@medicine.umaryland.edu
Elizabeth A Streeten, MD, Principal Investigator
Additional Information
Starting date: December 2013
Last updated: January 14, 2013
|
